A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita
Phase of Trial: Phase II/III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Pachyonychia congenita
- Focus Registrational; Therapeutic Use
- Acronyms VALO
- Sponsors Palvella Therapeutics
- 13 Nov 2019 According to a Palvella Therapeutics media release, the company is currently enrolling patients at nine sites across the US and data from this trial is expected in the second half of 2020.
- 13 Nov 2019 According to a Palvella Therapeutics media release, the company has commenced phase 3 portion of this trial.
- 12 Mar 2019 Status changed from planning to recruiting, according to a Ligand pharmaceuticals media release.